AIxCrypto Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Kevin Richardson

İcra Kurulu Başkanı

US$90.9k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.2yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Aug 16

Qualigen Therapeutics files mixed shelf offering of up to $150M

Jul 29

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Jul 06

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

Mar 08

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Nov 23

CEO

Kevin Richardson (57 yo)

1.2yrs

Görev süresi

US$90,907

Tazminat

Mr. Kevin A. Richardson, II, is CEO & Director of Qualigen Therapeutics, Inc. from September 26, 2024 and was its Interim CFO from September 26, 2024 and serves as its Chairman since 2024 and also serves a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Richardson	Co-CEO, Chief Accounting Officer & Chairman of the Board	no data	US$90.91k	Veri yok
Robert W. Becher	President	1.2yrs	US$88.00k	Veri yok
Michael Poirier	Chief Operating Officer	no data	US$686.53k	Veri yok
Christopher Lotz	VP of Finance & Corporate Secretary	2.8yrs	US$397.34k	Veri yok
Jiawei Wang	Co-Chief Executive Officer	less than a year	Veri yok	Veri yok
Koti Meka	Chief Financial Officer	less than a year	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: AIXC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Richardson	Co-CEO, Chief Accounting Officer & Chairman of the Board	1.2yrs	US$90.91k	Veri yok
Michael Gordon	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Anthony Tolcher	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Lillian Siu	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Wayne Klohs	Chair of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Patricia M. LoRusso	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Christopher Slapak	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Kevin Chen	Independent Director	less than a year	Veri yok	Veri yok
Graydon Bensler	Independent Director	1yr	Veri yok	Veri yok
Braeden Lichti	Independent Director	1.1yrs	US$25.00k	Veri yok
Stephen Neidle	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Jie Sheng	Director	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AIXC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/22 01:08
Gün Sonu Hisse Fiyatı	2025/11/21 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

AIxCrypto Holdings, Inc. 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
David Bautz	Zacks Small-Cap Research

AIxCrypto Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Appoints Jerry Wang as Co-CEO

High number of new and inexperienced directors

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Recent updates

AIxCrypto Holdings, Inc. Receives Letter of Non-Compliance with Nasdaq Listing Rule 5635(b) and Compliance with Nasdaq Listing Rule 5550(b)(1)

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. announced that it has received $41 million in funding from Faraday Future Intelligent Electric Inc., Sequoia Capital, IDgo, Inc., Circle Internet Group, Inc.

Qualigen Therapeutics, Inc. Appoints Jerry Wang as Co-CEO

Qualigen Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Qualigen Therapeutics, Inc. Announces Notice of Compliance Decision and Nasdaq Listing Status Update

New minor risk - Share price stability

New major risk - Negative shareholders equity

Qualigen Therapeutics, Inc. Provides Update on Nasdaq Listing Status

High number of new and inexperienced directors

Qualigen Therapeutics Receives Nasdaq Deficiency Notification for Delayed Filing

Qualigen Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered a non-binding Memorandum of Understanding to acquire Marizyme, Inc. (OTCPK:MRZM)

Qualigen Therapeutics, Inc. announced that it has received $5.1 million in funding

Qualigen Therapeutics, Inc. announced that it expects to receive $4.5 million in funding

Qualigen Therapeutics to Implement a 1-for-50 Reverse Stock Split, to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Qualigen Therapeutics, Inc. has filed a Follow-on Equity Offering.

Qualigen Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Audit Committee

Qualigen Therapeutics, Inc. Announces Board and Committee Changes

Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes

New major risk - Financial data availability

Less than half of directors are independent

The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity Rule

Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024

Qualigen Therapeutics, Inc. Announces Board Changes

Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)

Qualigen Therapeutics, Inc. announced delayed 10-Q filing

Qualigen Therapeutics, Inc. announced delayed annual 10-K filing

Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt

Consensus revenue estimates decrease by 14%, EPS upgraded

Qualigen Therapeutics Receives a Letter from the Nasdaq Stock Market

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Consensus EPS estimates fall by 57%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

New minor risk - Share price stability

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023

Price target decreased by 23% to US$27.00

Consensus revenue estimates decrease by 12%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302

Qualigen Therapeutics, Inc. Announces Executive Changes

Consensus forecasts updated

High number of new and inexperienced directors

High number of new and inexperienced directors

Consensus forecasts updated

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Price target decreased to US$5.75

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları